Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains?
03:50am, Tuesday, 10'th Feb 2026
Demand for weight loss drugs is high, and analysts predict the market may reach nearly $100 billion in a few years. Eli Lilly dominates the GLP-1 market in the U.S. We're bullish on these 10 stocks �
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?
04:07pm, Monday, 09'th Feb 2026
On Friday, the U.S. Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 ingredients in compounded drugs not approved by the agency. Last week, Hims & Hers announced plan
Chipotle Is Now Targeting the GLP-1 Market. Can This Move Turn Things Around for the Struggling Restaurant Chain?
12:29pm, Monday, 09'th Feb 2026
Chipotle recently launched new menu items that appear to be targeted at more diet-conscious consumers and those now using GLP-1 drugs. GLP-1 drugs suppress one's appetite.
Over 60% of Eli Lilly's Revenue Comes From Its GLP-1 Drugs. Should Investors Be Worried?
11:30am, Monday, 09'th Feb 2026
Eli Lilly's fourth-quarter revenue rose by 43%, largely a result of its impressive GLP-1 products. Sales from its GLP-1 drugs doubled, and they are key components of the company's business.
Novo Nordisk Stock Whipsawed by GLP-1 Pill Fears: Relief Ahead?
10:56am, Monday, 09'th Feb 2026
NVO shares swing sharply after fears over cheap compounded GLP-1 pills, before FDA action and a Hims retreat spark a sharp rebound.
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
09:30pm, Saturday, 07'th Feb 2026
Eli Lilly's stock price rose sharply as demand for its GLP-1 drugs increased. Novo Nordisk is the second fiddle in GLP-1 drugs, but its GLP-1 pill is seeing strong demand.
FDA Targets Hims & Hers, Other Marketers of Unapproved GLP-1 Weight-Loss Drugs
06:23pm, Friday, 06'th Feb 2026
The FDA said “decisive steps” will be taken to restrict drugs using GLP-1 active pharmaceutical ingredients in non-approved drugs.
San Francisco, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice.
New York, NY, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice.
The Commoditization Of GLP-1s: Why Viking's Maintenance Hedge Is Falling Short
06:03pm, Thursday, 05'th Feb 2026
Viking Therapeutics, Inc. faces significant challenges with VK2735, lacking differentiation from established obesity treatments like ZEPBOUND and WEGOVY. Phase 2 data highlight tolerability issues at
Why a $49 weight-loss pill is rattling Novo Nordisk and Eli Lilly
02:29pm, Thursday, 05'th Feb 2026
Novo Nordisk and Eli Lilly are facing an uncomfortable new price point this week after a $49 weight-loss pill jolted the GLP-1 market. By launching a low-cost, compounded oral version of semaglutide,
Structure Therapeutics' GLP-1 drug candidate, aleniglipron, has helped people lose up to 15% of their body weight. Its share price has tripled in the past year, suggesting investors have already price
Edible Garden to Participate in ECRM's Total Wellness: GLP-1, Weight Management, Nutrition & Vitamin Session, February 10–12, 2026
08:09am, Thursday, 05'th Feb 2026
BELVIDERE, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leading provider of controlled environment agricultur
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
02:51pm, Wednesday, 04'th Feb 2026
Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging a
Eli Lilly Is Dominating the GLP-1 Wars as Novo Nordisk Sales Tank
02:39pm, Wednesday, 04'th Feb 2026
The rivalry in the GLP-1 market between pharmaceutical leaders Eli Lilly ( NYSE:LLY ) and Novo Nordisk ( NYSE:NVO ) has intensified following their latest fourth-quarter earnings reports.
